Hematological adverse events and sustained viral response in children undergoing therapy for chronic hepatitis C infection

Hepatitis Monthly

Volumn 11, Issue 12, 2011, Pages 968-974

  Pawlowska, Malgorzata ^a   Pilarczyk, Malgorzata ^a   Foksinska, Anna ^a   Smukalska, Ewa ^a   Halota, Waldemar ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Child; Hepatitis C; Therapeutics

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; INFANT; LEUKOCYTE COUNT; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84855801331     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.789     Document Type: Article

References (19)

1. elisofon SA, Jonas MM. Hepatitis B and C in children: current treat-ment and future strategies. Clin Liver Dis. 2006;10(1):133-48, vii.
2. Mohan n, Gonzalez-peralta Rp, Fujisawa T, Chang MH, Heller S, Jara P, et al. Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr. 2010;50(2):123-31.
3. Cesaro S, Bortolotti F, petris MG, Brugiolo A, Guido M, Carli M. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer. 2010;55(1):108-12.
4. Sokal eM, Bourgois A, Stephenne X, Silveira T, porta G, Gardo-vska D, et al. peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52(6):827-31.
5. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52(4):501-7.
6. Sikorska K, Stalke p, Izycka-Swieszewska e, Romanowski T, Bielawski Kp. The role of iron overload and HFe gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit. 2010;16(3):CR137-43.
7. Karnsakul W, Alford MK, Schwarz KB. Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag. 2009;5(3):651-60.
8. Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J. 2002;21(5):479-81.
9. Gabriel A, Mietkiewski J, Ziolkowski A. [Current morphological classification of chronic liver inflammation: its merits and problems]. Pol J Pathol. 1999;50(4 Suppl 1):5-11.
10. Lodato F, Azzaroli F, Tame MR, Di Girolamo M, Buonfiglioli F, Mazzella N, et al. G-CSF in peg-IFn induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol. 2009;15(43):5449-54.
11. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11(3):243-50.
12. Turbide C, Soulellis C, Deschenes M, Hilzenrat N. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? Can J Gastroenterol. 2008;22(2):149-52.
13. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis. 2005;9(4):601-16, vi.
14. Manns Mp, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
15. nudo CG, Wong p, Hilzenrat n, Deschenes M. elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006;20(9):589-92.
16. Suwantarat n, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci. 2010;7(1):36-42.
17. ozaki H, Ishii K, Horiuchi H, Arai H, Kawamoto T, okawa K, et al. Cutting edge: combined treatment of TnF-alpha and IFn-gam-ma causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol. 1999;163(2):553-7.
18. pawlowska M, Jendryczka E, Halota W. Decrease of leukocytes count as a prognostic factor of treatment response in children with chronic hepatitis C treated with IFn-alpha and ribavirin. Int Rev Allergol Clin Immunol. 2006;12(3):100-2.
19. Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology. 2011;53(4):1109-17.